Form 4 for NRIX Nurix Therapeutics, Inc.

Accepted 2021-08-11 00:00:00 ET · period of report 2021-08-10 · accession 0001209191-21-050977 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-08-11	2021-08-10	NRIX	Ring Christine	GC	M - OptEx	$1.86	+1,200	2,005	+149%	+$2,232
D	2021-08-11	2021-08-10	NRIX	Ring Christine	GC	S - Sale+OE	$29.87	-1,200	805	-60%	-$35.8K
D	2021-08-11	2021-08-10	NRIX	Ring Christine	GC	M - OptEx	$0.00	-1,200	110.9K	-1%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-08-10	M	A	1,200	$1.86	2,005	D	—	—
2	Common	Common Stock	2021-08-10	S	D	1,200	$29.87	805	D	—	—	(F2) Represents the weighted average sale price. The lowest price at which shares were sold was $29.37 and the highest price at which shares were sold was $30.33. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein.
3	Derivative	Employee Stock Option (right to buy)	2021-08-10	M	D	1,200	$0.00	110,866	D	$1.86 · — to 2029-09-30	1,200 Common Stock	(F3) The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.